BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 171 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,058,123 | +73.0% | 40,126 | +12.9% | 0.02% | +100.0% |
| Q2 2023 | $611,563 | +15.8% | 35,556 | +11.7% | 0.01% | -11.1% |
| Q1 2023 | $527,907 | +112.9% | 31,840 | -2.1% | 0.01% | +80.0% |
| Q4 2022 | $247,947 | -48.5% | 32,539 | -32.8% | 0.01% | -37.5% |
| Q3 2022 | $481,000 | +8.6% | 48,400 | -0.7% | 0.01% | 0.0% |
| Q2 2022 | $443,000 | -94.8% | 48,748 | -94.2% | 0.01% | -89.9% |
| Q1 2022 | $8,578,000 | -39.2% | 845,075 | -0.0% | 0.08% | -1.2% |
| Q4 2021 | $14,099,000 | -60.2% | 845,260 | +11.9% | 0.08% | -56.5% |
| Q3 2021 | $35,402,000 | -23.4% | 755,322 | -0.3% | 0.18% | -18.9% |
| Q2 2021 | $46,206,000 | -1.9% | 757,973 | -0.9% | 0.23% | -10.6% |
| Q1 2021 | $47,110,000 | – | 764,767 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |